SCHEMBL2803955

SCHEMBL2803955

Cc1cc(=O)oc2cc(OCC(=O)O)ccc12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.80
KDM4E B2RXH2 6/20 0.80
HPGD P15428 5/20 0.80
AR P10275 1/20 0.74
KMT2A Q03164 3/20 0.72
MAPT P10636 3/20 0.72
TP53 P04637 2/20 0.72
HSD17B10 Q99714 2/20 0.72
MEN1 O00255 2/20 0.71
POLB P06746 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.67
AGER Q15109 1/20 0.67
KDR P35968 1/20 0.66
NPC1 O15118 2/20 0.66
MAOA P21397 1/20 0.66
MAOB P27338 1/20 0.66
CASP3 P42574 1/20 0.66
RAB9A P51151 1/20 0.66
SENP8 Q96LD8 1/20 0.66
SENP7 Q9BQF6 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29881770 1.00 ALDH1A1 (0.80) ALDH1A1KDM4EHPGDARKMT2A
SCHEMBL11316690 0.89 AR (0.74) ALDH1A1KDM4EHPGDARKMT2A
SCHEMBL5717615 0.88 AR (0.73) ALDH1A1KDM4EHPGDARKMT2A
SCHEMBL3210418 0.88 ALDH1A1 (0.79) ALDH1A1KDM4EHPGDARKMT2A
SCHEMBL15499731 0.86 ALDH1A1 (0.81) ALDH1A1KDM4EHPGDARKMT2A
SCHEMBL29677221 0.85 KMT2A (0.66) ALDH1A1KDM4EHPGDARKMT2A
SCHEMBL20364004 0.85 ALDH1A1 (0.77) ALDH1A1KDM4EHPGDARKMT2A
SCHEMBL9204774 0.85 KMT2A (0.66) ALDH1A1KDM4EHPGDARKMT2A
SCHEMBL14883408 0.85 ALDH1A1 (0.79) ALDH1A1KDM4EHPGDARKMT2A
SCHEMBL24198275 0.85 ALDH1A1 (0.74) ALDH1A1KDM4EHPGDKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113774021-B Preparation method of biological material bracket containing mesenchymal stem cell spheres 中国人民解放军陆军特色医学中心 2024-06-04 CN claimed
US-20230165965-A1 NEW COUMARIN-POLYMER CONJUGATES AND USES THEREOF ONYEL BIOTECH S.R.L. (IT) 2023-06-01 US claimed
EP-4138941-A1 NEW COUMARIN-POLYMER CONJUGATES AND USES THEREOF Onyel Biotech S.r.l. (IT) 2023-03-01 EP claimed
WO-2021214652-A1 NEW COUMARIN-POLYMER CONJUGATES AND USES THEREOF ONYEL BIOTECH S.R.L. (IT) 2021-10-28 WO claimed
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO claimed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO claimed
US-5663029-A DEVELOPMENT OF LATENT IMAGE, TRANSFERRING TO FORM RECORDING SHEETS, COATING A SUBSTRATE USING POLYMERS XEROX CORPORATION (US) 1997-09-02 US claimed
EP-4680227-A1 FORMULATIONS OF DANICOPAN AND METHODS OF USE THEREOF Alexion Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20250188018-A1 FORMULATIONS WITH IMPROVED STABILITY INSPIRNA INC (US) 2025-06-12 US disclosed
WO-2024191606-A1 FORMULATIONS OF DANICOPAN AND METHODS OF USE THEREOF ALEXION PHARMACEUTICALS, INC. (US) 2024-09-19 WO disclosed
US-20240200081-A1 NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE Aptacure Therapeutics Limited (CN) 2024-06-20 US disclosed
CN-113774021-B Preparation method of biological material bracket containing mesenchymal stem cell spheres 中国人民解放军陆军特色医学中心 2024-06-04 CN disclosed
EP-4316495-A1 NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE Aptacure Therapeutics Limited (HK) 2024-02-07 EP disclosed
US-5510343-A BETA-LACTAMASE INHIBITOR HOFFMANN-LA ROCHE INC. (US) 1996-04-23 US disclosed
US-5419966-A Solid support for synthesis of 3'-tailed oligonucleotides MICROPROBE CORPORATION (US) 1995-05-30 US disclosed
EP-0547142-A4 MICROPROBE CORP (US) 1995-01-18 EP disclosed
EP-0547142-A1 SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE EPOCH PHARMACEUTICALS, INC. (US) 1993-06-23 EP disclosed
WO-1992013092-A1 METHODS OF TRANSCRIPTIONALLY MODULATING EXPRESSION OF HEMATOPOIETIC GROWTH FACTOR GENES ONCOGENE SCIENCE, INC. (US) 1992-08-06 WO disclosed
WO-1992012635-A1 METHODS OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION OF VIRAL GENES AND OTHER GENES ONCOGENE SCIENCE, INC. (US) 1992-08-06 WO disclosed
WO-1992003464-A1 SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE MICROPROBE CORPORATION (US) 1992-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165965-A1 NEW COUMARIN-POLYMER CONJUGATES AND USES THEREOF CBR3, CYP3A43, CYP3A4 ALDH1A1 263/4885KDM4E 3146/4885HPGD 281/4885
US-20250188018-A1 FORMULATIONS WITH IMPROVED STABILITY FURIN, CEL, CTSA ALDH1A1 2703/4885KDM4E 3519/4885HPGD 739/4885
US-20240200081-A1 NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE SOST, FABP1, VEGFA ALDH1A1 892/4885KDM4E 4462/4885HPGD 4553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.